Moorestown, New Jersey, United States

7322321334

seeking biotech alpha

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™ seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

BiotecHeart™

image71

Welcome to BiotecHeart™

BiotecHeart will highlight product development progress

* pipelines/life-lines and research & development efforts 

* product presentations that involve clinical development progress

* product presentations that are presented at key meetings/conferences


Thank you visiting www.biotecheart.com

 

BiotecHeart™ - See The Light

danwatson888's Blog long only, Deep Value, dividend growth investing, healthcare

 

BiotecHeart™ - See The Light

Feb. 20, 2020 10:20 AM ET|About: Amarin Corporation plc (AMRN), BMY, (BDX), GILD, JNJ, MRK, NVO, NVS, PFE, RHHBY, ABBV

Summary

The political and socio-economic environment in America, is both depressing and disconcerting.


The hostility increases towards everyone connected with the biotech/drug industry during this highly politically charged season.


Politicos still see little to no value in biotech companies and continue to vilify them.


There continues to be much encouraging news and positive clinical tests in the biotech world, including on the coronavirus situation, for the first 2 months of 2020.

image72

 

BiotecHeart™ - See The Light

https://seekingalpha.com/instablog/5205071-danwatson888/5411014-biotecheart-see-light

BiotecHeart™ - See The Light

Feb. 20, 2020 10:20 AM ET|About: (AMRN), BMY, BDX, GILD, JNJ, MRK, NVO, NVS,

 Summary


The political and socio-economic environment in America, is both depressing and disconcerting.


The hostility increases towards everyone connected with the biotech/drug industry during this highly politically charged season.


Politicos still see little to no value in biotech companies and continue to vilify them.


 BiotecHeart™ - See The Light 

 https://seekingalpha.com/instablog/5205071-danwatson888/5411014-biotecheart-see-light 


There continues to be much encouraging news and positive clinical tests in the biotech world, including on the coronavirus situation, for the first 2 months of 2020.

image73

BiotecHeart™ “Joy Unto The World”

Dec. 24, 2019 6:27 AM ET

 Summary

this has been the “Biotech Decade” 2010-2019.


this year has been the “Biotech Year”.


Based on the current political environment it has been a spectacular year for the healthcare sector, and for many biotech companies.

danwatson888's Blog long only, Deep Value, dividend growth investing, healthcare

  Dec. 24, 2019 6:31 AM ET|About: AbbVie Inc. (ABBV), ABMD, ABT, AMGN, AMRN, AZN, BGNE, BIIB, BLUE, BMRN, BMY, GILD, ISRG, JNJ, LLY, MDT, MRK, NVS, PFE, REGN, RHHBY, SGEN, SRPT, VRTX 

image74

BiotecHEART™-Breakthrough

Dec. 9, 2019 8:35 AM ET|About: AbbVie Inc. (ABBV), ALPMY, BMY, CELG, JNJ, MRK, PFE, RHHBY, SGEN

 Summary


There is no impossible.


2019, has been a breakthrough year for all who need medicine.


many clinical tests involving combinations of successful medicines.


many approvals this year in China for successful medicines.

danwatson888's Blog long only, Deep Value, dividend growth investing, healthcare

 

BiotecHEART™-Breakthrough

Dec. 9, 2019 8:35 AM ET|About: AbbVie Inc. (ABBV), ALPMY, BMY, CELG, JNJ, MRK, PFE, RHHBY, SGEN 

BiotecHeart™

image75
image76

life-lines

SAGE - Sage Therapeutics, Inc.

SAGE - Sage Therapeutics, Inc.

SAGE - Sage Therapeutics, Inc.

 

Pipeline

Advancing a Leading Brain Health Portfolio

Our differentiated approach to drug discovery and development has allowed us to create a broad portfolio of fully-owned product candidates with the potential for development in a wide range of psychiatric, neurological and related central nervous system (CNS) disorders.

ZYME - Zymeworks Inc.

ICPT - Intercept Pharmaceuticals, Inc.

SAGE - Sage Therapeutics, Inc.

 We currently have two wholly-owned product candidates in clinical development and several wholly-owned product candidates in preclinical development that leverage our multiple therapeutic platforms to address areas of significant unmet medical need.  

ICPT - Intercept Pharmaceuticals, Inc.

ICPT - Intercept Pharmaceuticals, Inc.

ICPT - Intercept Pharmaceuticals, Inc.

 

PIPELINE

Novel compounds being developed for liver diseases

CRSP - CRISPR Therapeutics AG

ICPT - Intercept Pharmaceuticals, Inc.

ICPT - Intercept Pharmaceuticals, Inc.

. We have established a portfolio of programs by selecting disease targets based on a number of criteria, including unmet medical need, technical feasibility, advantages of CRISPR/Cas9 relative to other approaches and time required to advance the product candidate into and through clinical trials. 

life-lines

SRPT

SRPT

SRPT

image78

 Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for six Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. 

ALXN

SRPT

SRPT

image79

 We’re building on our fundamental understanding of complement biology and advancing on our core therapeutic areas of hematology, nephrology, neurology, metabolics, and cardiology. We continue to evolve into new areas where there is great unmet need and opportunity to help people living with rare diseases and their families fully live their best lives. 

NKTR

SRPT

TSE Code 4502

image80

 

Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We are focused on using new chemistry approaches to make better medicines to treat cancer, chronic pain and auto-immune disease.

Nektar Therapeutics also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.

TSE Code 4502

Private company

TSE Code 4502

image81

 

We are committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.  We focus on our R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Disease.  We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

Key Products and Pipeline (FY2019 Q2 Pipeline Table)

Click to download(PDF)

SNY

Private company

Private company

image82

 As researchers, we are passionate about scientific excellence because what we do today may improve the lives of people tomorrow. We work to transform scientific knowledge and medical advances into cutting-edge therapies to improve people’s lives worldwide. Discovering solutions for the world’s most pressing medical needs is our top priority. 

Private company

Private company

Private company

image83

 Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation. With a pipeline of around 90 clinical and pre-clinical projects, with the potential to deliver up to 15 new medicines by 2025, we continue our track record of long-term innovation-led performance. 

life-lines

AVEO

AVEO

AVEO

image84

 AVEO Pharmaceuticals is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company’s lead candidate is tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, which AVEO is seeking to develop and commercialize in North America as a treatment for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and other cancers. Tivozanib (FOTIVDA®) is approved by the European Commission for the treatment of adult patients with advanced RCC in the European Union plus Norway, New Zealand and Iceland. AVEO is leveraging or seeks to leverage partnerships to develop and commercialize its pipeline of products and product candidates, including tivozanib in oncology and other indications in various geographies, and ficlatuzumab (HGF MAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia. AVEO’s earlier-stage pipeline includes AV-203 (anti-ErbB3 MAb), AV-380 (GDF15 MAb) and AV-353 (Notch 3 MAb) drug candidates being developed for various oncology indications. 

KRTX

AVEO

AVEO

image85

 Our pipeline is built on the broad therapeutic potential of our lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. 

ALNY

AVEO

ALNY

image86

 Alnylam is leading the translation of RNAi (RNA interference) into a whole new class of innovative medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need that fall under 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS) and ocular diseases. .

HRTX

HRTX

ALNY

image87

 We are currently developing and commercializing pharmaceutical products for patients suffering from cancer or postoperative pain. Our goal is to develop each of our products with patients' needs at the center of our focus, and to deliver products with best-in-class therapeutic potential.  

VCYT

HRTX

VCYT

image88

 

PIPELINE

Our product pipeline expands on our founding strategy to improve diagnostic accuracy by answering clinical questions in our indications further across the clinical care continuum, including early detection and informing treatment decisions. We also continue to evaluate intellectual property and corporate acquisitions that we believe answer clinically meaningful questions and enable better patient outcomes. We believe the global market opportunity for our products is over $30 billion annually.

NBIX

HRTX

VCYT

image89

 

Pipeline Overview

life-lines

MRK

RHHBY

BIIB

image90

 

Scientific curiosity drives us to invent solutions to some of the world's most challenging diseases.

Many begin in Merck Research Laboratories (MRL), where we focus on discovering and developing therapies to improve patients' lives.

RHHBY

RHHBY

RHHBY


 Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) 

 https://www.roche.com/dam/jcr:4fcd49b1-bcd5-4714-96ed-2589d7413548/en/irp180426-annex.pdf 

 

PIPELINE

 https://www.gene.com/medical-professionals/pipeline 


 

Roche Holding (RHHBY) Presents At 2019 ASH Annual Meeting - Slideshow

Dec. 10, 2019 2:42 PM ET | About: Roche Holding AG (RHHBY) 

 https://seekingalpha.com/article/4311694-roche-holding-rhhby-presents-2019-ash-annual-meeting-slideshow 

LLY

LLY

RHHBY

 

MEDICINES IN DEVELOPMENT

MOLECULE & POTENTIAL INDICATION DATA AS OF OCTOBER 21, 2019

Interested in Lilly clinical trials? Learn more at LillyTrialGuide.com

 https://www.lilly.com/discovery/pipeli


ne 

AMGN

LLY

AMGN

 A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success. 

 https://www.amgenpipeline.com/pipeline/ 

life-lines

CELG

LOXO

CELG

image91

BMY

LOXO

CELG

 

In The Pipeline

Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients.

 https://www.bms.com/researchers-and-partners/in-the-pipeline.html 

LOXO

LOXO

LOXO

image92

PFE

REGN

LOXO

 

PRODUCT PIPELINE

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

 https://www.pfizer.com/science/drug-product-pipeline 

REGN

REGN

REGN

 

Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

 https://www.regeneron.com/pipeline 

life-lines

GILD

GILD

GILD

 Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need. 

 https://www.gilead.com/science-and-medicine/pipeline 

ABBV

GILD

GILD

 

Advanced medicines that demonstrate both strong clinical performance and strong economic value

(Select pipeline highlights as of January 2019)

 https://www.abbvie.com/our-science/pipeline.html 

BMRN

BMRN

BMRN

 

BioMarin has developed and commercialized a growing list of innovative biopharmaceuticals for rare diseases driven by genetic causes since 1997, a testament to the company’s passion and dedication to patients with serious unmet medical needs.

 https://www.biomarin.com/products+and+pipeline+overview 

VRTX

BMRN

VRTX

 

A Pathway to the Future

We’re focused on developing transformative medicines for people with serious and life-threatening diseases. 

 https://www.vrtx.com/research-development 

SGEN

BMRN

VRTX

image94

 

Strong Development Pipeline

A diverse pipeline designed to address significant unmet medical needs

We are focused on developing a new generation of targeted, empowered therapies with the goal of advancing the foundation of care. In addition to a comprehensive development program to further expand ADCETRIS® (brentuximab vedotin), our robust pipeline is designed to address significant unmet medical needs.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

 https://www.seattlegenetics.com/pipeline 

life-lines

EXEL

EXEL

EXEL

 The Exelixis pipeline includes our lead compounds, cabozantinib and cobimetinib, as well as other programs that are the subject of partnerships and collaborations with several biopharmaceutical companies. An additional wholly owned compound, XL888, is the subject of ongoing clinical research through our Investigator-Sponsored Trial program. Safety and efficacy for these compounds in the unapproved uses or indications described below have not yet been established. 

 https://www.exelixis.com/pipeline/ 



AGN

EXEL

EXEL

 Allergan is focused on driving innovation in four core therapeutic areas. As part of our approach to delivering innovation for better patient care, we have built one of the broadest pharmaceutical and device research and development pipelines in the industry. 

 https://www.allergan.com/research-and-development/pipeline 



BGNE

EXEL

BGNE

 

BeiGene
Pipeline

We are advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. We have three internally-developed late-stage clinical drug candidates and three marketed products in China.

 https://www.beigene.com/science-and-product-portfolio/pipeline 

XON

SGMO

BGNE

 

We are a community of scientists and creative innovators working to build a safer, healthier planet, and a more promising future.

Our unique expertise is in the design and engineering of astonishing living systems, from T-cells that battle cancer to non-browning apples. Across our diverse portfolio of projects we apply a common philosophy: bring together the greatest minds in synthetic biology and empower them to solve big problems.

We’re developing solutions through intrexon Health and intrexon Bioengineering. intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, energy, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency.

 https://www.dna.com/ 


SGMO

SGMO

SGMO

 

HERAPEUTIC PROGRAMS UNDER DEVELOPMENT

Our strategy is to retain and develop product candidates ourselves in certain therapeutic areas that meet key criteria including having breakthrough potential for unmet needs; where development and commercialization are financially and operationally feasible; and where we see synergies across our product candidates and therapeutic approaches.

We are focusing our proprietary pipeline on research and development of product candidates for inherited metabolic diseases, central nervous system diseases, and immunology.

Collaboration is critical to maximizing the value of our platform technology and has brought important funding and expertise to our research. We will continue to collaborate, especially in therapeutic areas that are highly competitive or that require special disease area expertise or resources.

 https://www.sangamo.com/pipeline 

NVO

SGMO

SGMO

image95

 

We discover, develop and deliver

We are passionate about translating patients' unmet medical needs into novel ideas for therapeutic solutions. As a global provider of advanced treatments for diabetes and other serious chronic diseases, our goal is always to discover and develop innovative biological medicines and make them accessible to patients throughout the world.

 https://www.novonordisk.com/research-and-development/our-therapy-areas.html 

Accessing your medicines can be confusing. It doesn’t have

image96

About MAT.org PhRMA’s Medicine Assistance Tool (MAT) is a search engine designed to help patients, caregivers and health care providers learn more about the resources available through the various biopharmaceutical industry programs. MAT is not its own patient assistance program, but rather a search engine for many of the patient assistance resources that the biopharmaceutical industry offers.

.

Authorized generics of NovoLog® and NovoLog Mix®

image97

Novo Nordisk's new insulin affordability offerings now available in the US

image98

Bernard Munos Contributor

 Jan 14, 2019, 07:44am  Bernard Munos Contributor
 

2018 New Drugs Approvals: An All-Time Record, And A Watershed

Bernard Munos Contributor

 I study pharmaceutical innovation, what causes it and how to get more of it. Several of my papers, published in Nature and Science, have helped stimulate a rethinking of the industry business model. In 2012, the popular newsletter FiercePharma named me one of the 25 most influential people in biopharma. In 2013, I became a Senior Fellow at FasterCures (a center of the Milken Institute). Besides doing research, I spend a lot of time helping organizations – big, small, public, private, US and non-US – become better innovators. I learned my trade in the 30 years I spent in the industry at Eli Lilly. Before that, I trained as an animal scientist in France and earned additional degrees in business and economics from Stanford and UC-Davis. I serve on various boards and advisory bodies, including at NCATS, the Institute of Medicine, Glenmark Pharmaceuticals, think tanks and foundations.